This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Treat to Target: Raising the Bar to Control Moderate to Severe Plaque Psoriasis With Interleukin Inhibition

Treat to Target: Raising the Bar to Control Moderate to Severe Plaque Psoriasis With Interleukin Inhibition



Time to Complete

1.25 hours


October 31, 2018


October 31, 2019
Add to Queue

Maximum Credits

1.25 / AMA PRA Category 1 CreditsTM

Accredited Provider

Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Novartis Pharmaceuticals Corporation

Program Description

Psoriasis is a common, chronic, immune-mediated, inflammatory condition that is now considered a systemic disease with multiple comorbidities, many of which are related to cardiovascular disease.

Unfortunately, expert guidelines have not kept pace with the emergence of new treatments for the condition, and a number of gaps have been identified between best practices in the management of psoriasis and what actually transpires in routine clinical care.

In response to those shortfalls, this enduring myCME TOWN WALLTM  activity convenes a group of clinical experts to discuss evidence-based perspectives on the optimal management of moderate to severe plaque psoriasis, including the implementation of a treat-to-target approach that incorporates biologics, either alone or in combination with topical agents. This unique, interactive program was designed to engage learners as active participants while improving their ability to better utilize individualized, targeted therapeutic strategies for psoriasis that also address common comorbidities.

Intended Audience

This activity is designed for dermatologists, primary care clinicians (family medicine and internal medicine [IM] physicians, nurse practitioners [NPs], and physician assistants [PAs]), and other clinicians who care for patients with psoriasis.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Assess the impact of poorly controlled moderate to severe plaque psoriasis on patient quality of life
  • Describe the mechanisms of action, efficacy, and safety profiles of new treatment options for psoriatic disease, including phosphodiesterase-4 (PDE-4), interleukin (IL)-23, and IL-17 inhibitors
  • Implement individualized, targeted treatment strategies based on disease severity and prior treatment modalities
  • Address associated comorbidities to maximize clinical and functional outcomes

Conflict Of Interest Disclosure Policies

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.


Peter Salgo, MD

Professor of Medicine and Anesthesiology
Columbia University College of Physicians and Surgeons
Associate Director, Surgical Intensive Care
Columbia University Medical Center
New York, NY

Dr. Salgo has no relevant financial relationships to disclose.

Joel M. Gelfand, MD, MSCE

Professor of Dermatology and Epidemiology
Vice Chair, Clinical Research
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

Dr. Gelfand serves as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GSK, Janssen Biologics, Novartis, Pfizer, Inc., Regeneron, Sanofi, and UCB (data safety monitoring board). He has also received honoraria and research support (to the Trustees of the University of Pennsylvania) from AbbVie, Celgene, Janssen Biologics, Novartis, Ortho Dermatologics, Pfizer, Inc., and Sanofi, and he is a co-patent holder of resiquimod for the treatment of cutaneous T-cell lymphoma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Dr. Lebwohl has received research support from AbbVie, Boehringer lngelheim, Celgene, Eli Lilly, lncyte, Janssen/Johnson & Johnson, LEO Pharma, MedImmune/AstraZeneca, Novartis, Pfizer, Inc., SCIderm, UCB, Valeant, and Vidac. He is also a consultant for Allergan, Aqua Pharmaceuticals, Boehringer lngelheim, LEO Pharma, Menlo Therapeutics, Mitsubishi Tanabe Pharma America, Promius Pharma, and Theravance Biopharma.

Neil J. Korman, MD, PhD
Professor of Dermatology
University Hospitals Cleveland Medical Center
Cleveland, OH

Dr. Korman serves as a consultant for Novartis and is an advisory board member for AbbVie, Celgene, Eli Lilly, Genentech, GSK, Immune Pharmaceuticals, Janssen, Principia Biopharma, Regeneron, Sun Pharmaceuticals, and Valeant. He also receives research support as an investigator for Celgene, Dermira, Eli Lilly, LEO Pharma, Merck & Co., Inc., Pfizer, Inc., Prothena, Regeneron, Rhizen Pharmaceuticals S.A., and UCB and has received honoraria as a speaker for AbbVie, Eli Lilly, Janssen, and Novartis.

Jashin J. Wu, MD
Medical Board Member
National Psoriasis Foundation
Portland, OR
Councilor, International Psoriasis Council
St. Louis, MO

Dr. Wu serves as a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Sun Pharmaceutical, and UCB. He also serves on the speakers’ bureaus for Celgene, Novartis, Sun Pharma, and UCB and receives research support from AbbVie, Amgen, Eli Lilly, Janssen, and Novartis.

Wendy Cantrell, DNP, CRNP

Associate Professor
UAB School of Medicine
Department of Dermatology
Birmingham, AL

Ms. Cantrell serves as a consultant for Eli Lilly, Janssen, and Novartis and serves on the speakers’ bureaus for Eli Lilly, Janssen, LEO Pharma, Novartis, and Sun Pharmaceutical.

Scott Freeman MS, PA-C
Physician Assistant
Advanced Dermatology
St. Petersburg, FL

Mr. Freeman has no relevant financial relationships to disclose.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 Category 1 Credits for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Astellas Pharma US, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the CME accreditation of this activity, please contact please contact HME at

If you have any other questions relating to your certificate or other issues with the activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue